

## Relative Contributions of Pulse Pressure and Arterial Stiffness to Cardiovascular Disease The Framingham Heart Study

Teemu J. Niiranen, Bindu Kalesan, Gary F. Mitchell, Ramachandran S. Vasani

**Abstract**—Pulse pressure has been frequently used as a surrogate marker of arterial compliance. However, the prevalence and prognostic significance of mismatch between pulse pressure and arterial stiffness remains unclear. We measured carotid-femoral pulse wave velocity (CFPWV) and central pulse pressure (CPP) in 2119 Framingham Offspring Cohort participants (mean age, 60 years; 57% women). The participants were divided into 4 groups according to CPP and CFPWV status (categorized as high/low based on  $\geq$ age- and sex-specific median values) and followed up for cardiovascular disease (CVD) events. At baseline, 832 of 2119 (39%) participants had discordant CPP and CFPWV status, 417 with low CPP and high CFPWV, and 415 with high CPP and low CFPWV. The multivariable-adjusted risk for CVD events ( $n=246$ ; median follow-up, 12.6 years) in individuals with a CPP-CFPWV mismatch (hazard ratio for low CPP with high CFPWV, 1.21; 95% CI, 0.83–1.76; hazard ratio for high CPP with low CFPWV, 0.76; 95% CI, 0.49–1.19) was comparable with the CVD risk observed in the low CPP with low CFPWV (referent group). In contrast, participants with a high CPP with high CFPWV (hazard ratio, 1.52; 95% CI, 1.10–2.11) experienced significantly increased CVD risk. The interaction term between CPP and CFPWV status on CVD risk was borderline significant in the multivariable model ( $P=0.08$ ). Our results demonstrate that pulse pressure-arterial stiffness mismatch is common in the community. CFPWV may modify the association of CPP with CVD risk, with the greatest risk being observed in those with elevated CPP and CFPWV. (*Hypertension*. 2019;73:712-717. DOI: 10.1161/HYPERTENSIONAHA.118.12289.) • [Online Data Supplement](#)

**Key Words:** arteries ■ cardiovascular diseases ■ hypertension ■ risk factors ■ vascular diseases

Increased pulse pressure and arterial stiffness are both associated with elevated risk of cardiovascular disease (CVD).<sup>1,2</sup> Pulse pressure and arterial stiffness are strongly correlated because age-associated vascular calcification and elastin breakdown leads to arterial stiffening, which in turn results in larger forward wave amplitude, earlier reflected wave arrival, and a greater pulse pressure.<sup>3,4</sup> Although not a direct measure of arterial stiffness, pulse pressure has been often used as a surrogate marker of arterial compliance.<sup>5</sup> However, major gaps still exist in our understanding of the interplay between pulse pressure and aortic stiffness. Albeit pulse pressure is sometimes used as a surrogate marker of arterial stiffness, the prevalence and prognostic significance of a mismatch between pulse pressure and arterial stiffness in the community have not been well studied. Such information could be of interest to elucidate the validity of pulse pressure as a surrogate measure of arterial stiffness. In addition, these data could help clinicians understand the relative and joint importance of pulse pressure and arterial stiffness in the assessment and pathogenesis of CVD risk.

To clarify the prevalence and predictive value of pulse pressure-arterial stiffness mismatch, we assessed measures of central hemodynamics and large artery stiffness in 2119 community-dwelling individuals and studied the relations of pulse pressure-arterial stiffness mismatch to the prevalence of left ventricular hypertrophy (LVH—a marker of cardiovascular target organ damage) cross-sectionally and to the incidence of CVD prospectively.

### Methods

Anonymized data have been made publicly available at the database of Genotypes and Phenotypes and can be accessed at <https://www.ncbi.nlm.nih.gov/gap/>.

### Participants

We included individuals who attended the seventh examination of the Framingham Offspring cohort ( $n=3539$ ; 1998–2001) in the present investigation. The characteristics and study protocol for the Framingham Heart Study Offspring cohort have been published.<sup>6</sup> Tonometry measurements were obtained in 2660 participants as described previously.<sup>3,7</sup> We excluded participants who had

Received October 24, 2018; first decision November 6, 2018; revision accepted December 30, 2018.

From the Framingham Heart Study, MA (T.J.N., R.S.V.); Department of Medicine, Turku University Hospital and University of Turku, Finland (T.J.N.); Department of Public Health Solutions, National Institute for Health and Welfare, Turku, Finland (T.J.N.); Center for Clinical Translational Epidemiology and Comparative Effectiveness Research (B.K., R.S.V.), Section of Preventive Medicine, Department of Medicine (B.K., R.S.V.), Evans Department of Medicine and Whitaker Cardiovascular Institute (R.S.V.), and Section of Cardiology, Department of Medicine (R.S.V.), Boston University School of Medicine, MA; Cardiovascular Engineering, Inc, Norwood, MA (G.F.M.); and Department of Epidemiology, Boston University School of Public Health, MA (R.S.V.).

The online-only Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.118.12289>.

Correspondence to Teemu J. Niiranen, Framingham Heart Study, 73 Mt Wayte Ave, Suite 2, Framingham, MA 01702. Email [teemu.niiranen@thl.fi](mailto:teemu.niiranen@thl.fi)

© 2019 American Heart Association, Inc.

*Hypertension* is available at <https://www.ahajournals.org/journal/hyp>

DOI: 10.1161/HYPERTENSIONAHA.118.12289

incomplete tonometry data (n=367) or prevalent CVD (n=174) from the present analysis.

Measurements for echocardiographic and electrocardiographic LVH were performed during the participants' previous sixth examination cycle (1995–1998). A subpopulation of 1579 participants with ECG and echocardiography data available from the sixth examination cycle was used for analyses of LVH. Boston University Medical Center Institutional Review Board approved all study protocols, and participants provided written informed consent.

### Clinical Evaluation and Definitions

All participants provided a medical history and underwent laboratory assessment of CVD risk factors and a physical examination.<sup>6</sup> We assessed the participants for the prevalence of diabetes mellitus (fasting glucose level of  $\geq 126$  mg/dL or the use of antidiabetic medications), and self-reported smoking. We measured blood pressure using a standardized protocol (mean of 2 auscultatory values obtained by a physician using a mercury column sphygmomanometer on the left arm of seated participants), body mass index, serum total cholesterol levels, and high-density lipoprotein cholesterol concentrations. We derived heart rate from a standard 12-lead ECG.

### Carotid-Femoral Pulse Wave Velocity and Central Pulse Pressure

We evaluated arterial stiffness with carotid-femoral pulse wave velocity (CFPWV).<sup>8</sup> We acquired arterial tonometry measures from the right side of the body after  $>5$  minutes of rest in the supine position as described previously.<sup>3,7</sup> Arterial tonometry with a simultaneously acquired ECG was obtained for the femoral and carotid arteries. We estimated the carotid-femoral transit distance by measuring the body surface distance from the suprasternal notch to the carotid and femoral sites and taking the difference to account for parallel transmission along the brachiocephalic and carotid arteries and around the aortic arch. We divided this corrected distance by the carotid-femoral transit time delay to calculate CFPWV.

We used the oscillometric systolic and diastolic cuff blood pressures obtained at the time of the tonometry acquisition to calibrate the peak and trough of the signal-averaged brachial pressure waveform. We used the diastolic and integrated mean brachial pressures to calibrate carotid pressure tracings.<sup>9</sup> We defined central pulse pressure (CPP) as the difference between the peak and trough of the calibrated carotid pressure waveform.

### Left Ventricular Hypertrophy

We defined LVH as a composite of presence of electrocardiographic or echocardiographic LVH. We defined LVH by ECG according to the Cornell voltage criteria (sum of R wave in aVL plus S wave in V3  $>20$  mV in women and  $>28$  mV in men).<sup>10</sup> We performed 2-dimensional echocardiography with Doppler color flow imaging using a Sonos 1000 Hewlett-Packard ultrasound device at the sixth examination cycle ( $\approx 3$  years preceding the CFPWV measurements). Digitized images were stored and measured using an off-line analysis system by certified sonographers or cardiologists. We measured left ventricular mass according to the American Society of Echocardiography guidelines.<sup>11</sup> We defined echocardiographic LVH as values of left ventricular mass index  $>115$  g/m<sup>2</sup> in men and  $>95$  g/m<sup>2</sup> in women.<sup>11</sup>

### CVD Outcomes

We used the incidence of a major CVD disease event as the primary outcome. This was a composite outcome that consisted of CVD death, fatal or nonfatal myocardial infarction, heart failure, unstable angina (prolonged ischemic episode with documented reversible ST-segment changes), and stroke. Medical records were obtained for all hospitalizations and physician visits related to CVD events during follow-up and were reviewed by an adjudication panel consisting of 3 investigators. Clinical criteria for adjudication of these CVD events have remained mostly unchanged during the duration of The Framingham Heart Study and been described previously.<sup>12</sup>

### Statistical Methods

We divided the participants into 4 groups according to their CPP status (CPP under versus  $\geq 5$ -year age- and sex-specific median) and presence of high vascular stiffness (CFPWV under versus  $\geq 5$ -year age- and sex-specific median) at the seventh examination cycle. We used age- and sex-specific cutpoints to partition participants into categories (of CPP and CFPWV) because these 2 factors are key correlates of CPP and CFPWV. Participants with low CPP and low CFPWV were used as the referent group in all analyses.

First, we used Pearson correlation to assess correlation between CFPWV and CPP. To reduce the impact of heteroscedasticity (the SD increases with mean value across various groupings, such as age), we inverted CFPWV and multiplied by  $-1000$  to restore directionality, resulting in a variable with a normal distribution and uniform SD. We log-transformed CPP to achieve normal distribution. Second, we assessed baseline characteristics according to the 4 groups cross-classified by CPP and CFPWV status. Third, we studied the associations between the 4 groups defined above and the presence of LVH cross-sectionally using multivariable-adjusted logistic regression models (adjusting for covariates noted below). Fourth, we evaluated the association between the 4 participant groups and incidence of CVD events with Kaplan-Meier plots (compared with a log-rank test) and multivariable-adjusted Cox proportional hazards regression models. The statistical interaction between the exposure categories (high/low CFPWV and high/low CPP) was tested by entering these variables as interaction terms into the multivariable models. We also tested for the statistical interaction between the 4-category exposure variable and age ( $<65$  versus  $\geq 65$  years) by entering these variables as interaction terms into the multivariable models while removing continuous age from the covariates. Improvement in discrimination was assessed using the C statistic for conventional cardiovascular risk factors and change in C statistic from addition of the 4-category exposure variable. In addition, we performed a secondary analysis in the subsample of participants who had data for LVH available (n=1579) by including LVH among the covariates. We also performed another secondary analysis while including antihypertensive medication in the covariates and using overall medians as the cutoffs as the original age- and sex-specific groupings increased the sensitivity of the groups to antihypertensive medication. The assumption of proportionality of hazards was met when we evaluated Schoenfeld residuals. We adjusted all multivariable models for age, sex, body mass index, smoking status, diabetes mellitus, heart rate, serum total cholesterol, and HDL cholesterol. A 2-sided value of  $P < 0.05$  was considered statistically significant for main effects, and a  $P < 0.10$  was deemed significant for tests of interactions.<sup>13</sup> All analyses were performed with Stata software, version 13.1 (StataCorp, College Station, TX).

### Results

We studied  $\leq 2119$  community-dwelling participants (mean age, 60.4 years; 56.6% women). Baseline characteristics in groups according to their CPP and CFPWV status are shown in Table 1. We found discordant CPP and CFPWV status in 832 of 2119 participants (39%): 417 with low CPP and high CFPWV and 415 with high CPP and low CFPWV. Apart from hemodynamic variables, differences between groups were mostly unremarkable except for the 2 groups with low CFPWV had lower heart rate and lower prevalence of diabetes mellitus than the 2 groups with high CFPWV. The age- and sex-adjusted correlation between CPP and CFPWV was  $r=0.44$  (Figure 1).

### Presence of LVH in Groups by CPP and CFPWV Status

In a subgroup of 1579 participants who had LVH data available (mean age,  $60.0 \pm 9.4$ ; 59.8% women), the prevalence of LVH in groups by CPP and CFPWV status is reported in

Table 1. Baseline Characteristics by CPP and Pulse Wave Velocity Status

Characteristic	All	Low CPP With Low CFPWV	Low CPP With High CFPWV	High CPP With Low CFPWV	High CPP With High CFPWV
n	2119	643	417	415	644
Age, y	60.4±9.5	60.6±9.4	60.2±9.6	60.3±9.5	60.6±9.5
Women, n	1203 (56.6%)	362 (56.3%)	237 (56.8%)	237 (57.1%)	364 (56.5%)
BMI, kg/m <sup>2</sup>	27.3±4.6	26.3±4.0	27.7±4.7	26.6±4.2	28.5±4.9
CPP, mm Hg	50.6±16.3	39.5±8.3	39.7±9.0	59.2±13.4	63.0±15.4
CFPWV, m/s	9.9±3.4	8.1±1.6	11.2±3.4	8.3±1.6	12.0±4.0
Systolic BP, mm Hg	127±19	116±14	125±16	126±17	139±20
Diastolic BP, mm Hg	74±10	71±9	76±10	73±8	78±10
Antihypertensive therapy, n	644 (30.4%)	142 (22.1%)	118 (28.3%)	106 (25.5%)	278 (43.2%)
Diabetes mellitus, n	186 (8.8%)	32 (5.0%)	51 (12.2%)	21 (5.1%)	82 (12.7%)
Current smoker, n	286 (13.5%)	94 (14.6%)	53 (12.7%)	57 (13.7%)	82 (12.7%)
Cholesterol, mmol/L	5.2±0.9	5.2±0.9	5.2±0.9	5.2±0.9	5.3±1.0
HDL cholesterol, mmol/L	1.4±0.4	1.5±0.5	1.4±0.4	1.5±0.4	1.4±0.4
Heart rate, beats/min	64.9±10.7	63.0±9.5	68.4±10.3	60.9±9.8	67.0±11.4

Values are mean±SD for continuous variables or n (%) for categorical variables. BMI indicates body mass index; BP, blood pressure; CFPWV, carotid-femoral pulse wave velocity; CPP, central pulse pressure; and HDL, high-density lipoprotein.

Table 2. In the unadjusted and multivariable-adjusted models, only the group with high CPP and high CFPWV was significantly related to the odds of prevalent LVH compared with the referent group with low CFPWV and low CPP. No statistical interaction was observed for the effects of CPP and CFPWV status on the prevalence of LVH ( $P=0.91$  in the multivariable model).

### Risk of CVD Events in Groups by CPP and CFPWV Status

During a median follow-up of 12.6 years, 246 CVD events occurred. The Kaplan-Meier curves in Figure 2 illustrate the cumulative incidence of CVD events in groups according to the CPP and CFPWV status (log-rank  $P<0.001$ ). In unadjusted Cox regression models, the hazard ratios for CVD events were significantly higher in the groups with (1) high CPP and high CFPWV and (2) low CPP and high CFPWV relative to the referent group with low CPP and low CFPWV. In the multivariable-adjusted model, only the group with high CPP and high CFPWV had a higher risk of incident CVD compared with the referent group. The interaction term between CFPWV and CPP status on CVD risk was borderline significant in the multivariable model ( $P=0.08$ ). The interaction term between the 4-category exposure variable and age on CVD risk was nonsignificant ( $P=0.82$ ). Addition of the 4-category CPP/CFPWV variable to the model without this variable did not increase the C statistic (Table 3). In a subsample of 1579 individuals, including LVH among the covariates resulted in the association of high CPP and high CFPWV with CVD outcomes becoming nonsignificant (Table S1 in the [online-only Data Supplement](#); hazard ratio, 1.41; 95% CI, 0.95–2.10;  $P=0.09$ ). When antihypertensive medication was included among the covariates, the results remained essentially same (Table S2).

### Discussion

The results of our study imply that pulse pressure-arterial stiffness mismatch is common, affecting 39% of individuals in the community when age- and sex-specific partition values are used to define high and low CPP and CFPWV. We observed that the combination of higher CPP and arterial stiffness was associated with a considerably elevated risk of LVH cross-sectionally and incidence of CVD prospectively. Higher arterial stiffness seems to be a more important driver of CVD risk because individuals with low CPP and high CFPWV tended to have an increased risk of prevalent LVH and incident CVD compared with individuals with high CPP and low CFPWV. We also observed an interaction between CFPWV and CPP status and CVD risk, demonstrating effect modification by arterial stiffness on the relations of pulse pressure to CVD risk.

Our results indicate that considerable disagreement between pulse pressure and arterial stiffness status exists in




Figure 1. Correlation between central pulse pressure and carotid-femoral pulse wave velocity.

**Table 2. Odds Ratios for Echocardiographic or Electrocardiographic LVH in Groups by CPP and Pulse Wave Velocity Status (n=1579)**

Group	n	Participants With LVH (%)	Unadjusted OR (95% CI)	P Value	Multivariable OR (95% CI)	P Value
Low CPP with low CFPWV	484	57 (11.8)	1.00 (reference)		1.00 (reference)	
Low CPP with high CFPWV	313	51 (16.3)	1.46 (0.97–2.19)	0.07	1.36 (0.88–2.09)	0.16
High CPP with low CFPWV	324	50 (15.4)	1.37 (0.91–2.06)	0.13	1.35 (0.89–2.07)	0.16
High CPP with high CFPWV	458	96 (20.9)	1.99 (1.39–2.84)	<0.001	1.86 (1.27–2.72)	0.001


Multivariable model is adjusted for age, sex, body mass index, smoking status, diabetes mellitus, heart rate, total cholesterol, and HDL cholesterol. LVH was defined as the presence of Cornell voltage >20 mV in women and >28 mV in men, left ventricular mass index >115 g/m<sup>2</sup> in men and >95 g/m<sup>2</sup> in women, or both. CFPWV indicates carotid-femoral pulse wave velocity; CI, confidence interval; CPP, central pulse pressure; HDL, high-density lipoprotein; LVH, left ventricular hypertrophy; and OR, odds ratio.

community-dwelling middle-aged adults. In our study, nearly two-fifths of the participants had discordant pulse pressure and arterial stiffness status based on the partition values used to define these categories. Consistent with the foregoing observation, the correlation between CPP and CFPWV was only moderate ( $r=0.43$ ). In prior smaller studies, correlation coefficients for peripheral pulse pressure and CFPWV have varied between  $-0.16$  and  $0.36$ .<sup>3,14–16</sup> When directly measured or tonometry-derived estimates of CPP have been used instead of peripheral pulse pressure, the correlation coefficients have been somewhat higher, ranging between  $0.52$  and  $0.64$ .<sup>8,17</sup> Furthermore, it has been previously demonstrated that a large part of the variation in CPP is not explained by measures of arterial stiffness.<sup>18–20</sup> The results from our and other prior studies suggest, therefore, that the pulse pressure and CFPWV are frequently discordant, and the correlation may be particularly weak when peripheral PP is used or in select populations, such as in young, healthy individuals<sup>15</sup> and in patients with lower limb ischemia.<sup>8</sup> Caution should be exercised, therefore, before using pulse pressure as a surrogate marker for arterial stiffness.

Previous studies that have assessed the prognostic significance of a CPP-CFPWV mismatch are extremely limited. In our search of the published literature, we noted only 1 prior study that had examined the relations of CPP/CFPWV ratio and critical limb ischemia in a sample of 136 South African patients and 194 age- and sex-matched controls.<sup>8</sup> In that study, the CPP/CFPWV ratio was increased in participants with critical limb ischemia and provided a similar level of accuracy and a greater specificity as compared with carotid

intimal-medial thickness.<sup>8</sup> However, the study evaluated a highly selected sample of patients with severe peripheral atherosclerosis, and the results may not be generalizable to other populations. The results of the present investigation suggest that the effects of CFPWV and CPP on the odds of LVH are additive. Although the differences were statistically nonsignificant in multivariable-adjusted models, participants with a CFPWV/ CPP mismatch had a higher odds of LVH that was intermediate between those observed for individuals with low CPP and low CFPWV and high CPP and high CFPWV. In contrast, individuals with low CFPWV did not have an increased risk of incident CVD, irrespective of CPP status and covariates. Furthermore, CFPWV status influenced the relations of CPP and CVD risk ( $P$  for interaction was  $0.08$ ). The exact physiological underpinnings of this finding require further research. Although including LVH as a covariate resulted in the association of high CPP and high CFPWV with CVD outcomes becoming nonsignificant, this finding must be interpreted with caution. Even though this analysis was performed in a smaller subsample of 1579 participants, which resulted in a considerable loss in statistical power, the association of high CPP and high CFPWV with CVD remained borderline significant with a hazard ratio of  $1.41$ . Additional studies of larger samples are, therefore, needed to elucidate the relative importance of PWV and LVH. In any case, physicians need to acknowledge that presence of both elevated CPP and CFPWV elevates the risk of incident CVD.

Several factors may explain the observed mismatch in CPP and CFPWV status. The 2 major components of CPP



**Figure 2.** Cumulative incidence of cardiovascular events in groups by central pulse pressure and pulse wave velocity status (truncated at 13 y after baseline).  $P$  for log-rank test <0.001. Data are for the unadjusted analysis. CPP indicates central pulse pressure; CVD, cardiovascular disease; and PWV, pulse wave velocity.

Table 3. Risk of Cardiovascular Events in Groups by CPP and Pulse Wave Velocity Status (n=2119).

Group	No. of CVD Events (%)	Events per 1000 Person-Years (95% CI)	Unadjusted HR (95% CI)	Multivariable HR (95% CI)
Low CPP with low CFPWV	60 (9.3)	8.4 (6.5–10.8)	1.00 (reference)	1.00 (reference)
Low CPP with high CFPWV	56 (13.4)	12.4 (9.5–16.0)	1.48 (1.03–2.13)*	1.21 (0.83–1.76)
High CPP with low CFPWV	29 (7.0)	6.1 (4.3–8.8)	0.73 (0.47–1.14)	0.76 (0.49–1.19)
High CPP with high CFPWV	101 (15.7)	14.8 (12.2–18.0)	1.79 (1.30–2.46)†	1.52 (1.10–2.11)*

Multivariable model was adjusted for age, sex, body mass index, smoking status, diabetes mellitus, heart rate, total cholesterol, and HDL cholesterol. The C statistic for a model that included only the covariates was 0.777 (95% CI, 0.745–0.804). Adding the 4-category exposure variable increased the model C statistic to 0.781 (95% CI, 0.754–0.808). The *P* value for the difference between C statistics was 0.27. CFPWV indicates carotid-femoral pulse wave velocity; CI, confidence interval; CPP, central pulse pressure; CVD, cardiovascular disease; HDL, high-density lipoprotein; and HR, hazards ratio.

\**P*<0.05.

†*P*<0.001.

are the first systolic shoulder in the arterial pulse waveform and the augmentation pressure.<sup>3,21</sup> Furthermore, the first shoulder of the arterial pulse waveform is mainly dependent on peak systolic flow rate and arterial stiffness, whereas augmentation pressure is determined by timing and amplitude of wave reflection. A prior study on 496 twins has indeed demonstrated that CFPWV is not a major determinant of arterial wave reflection and that the main determinant of the augmentation pressure is the ratio of distal-to-proximal arterial diameters.<sup>21</sup> These findings are also consistent with those from other studies that have shown that the dissociation between measures of wave reflection and CFPWV increases during interventions that influence vasomotor tone.<sup>22,23</sup> Results from our study and prior studies highlight that pulse pressure and arterial stiffness (CFPWV) are not the same and that physiological differences between the 2 hemodynamic variables exist.

Studying the separate roles of CPP and arterial stiffness as predictors of CVD outcomes has distinct challenges because CFPWV may be both a marker of hypertensive organ damage and also a precursor of hypertension. Furthermore, both arterial stiffness and hypertension may be part of a vicious cycle in the age-related increase in blood pressure.<sup>24</sup> Another challenge is that addition of the 4-category CPP/CFPWV variable to the model without this variable did not increase the C statistic. However, the primary objective of our investigation was to explore the conjoint impact of CPP and PWV on CVD risk, rather than CVD risk prediction per se. Furthermore, increments in C statistic with addition of biomarkers associated with CVD risk can often be challenging to achieve.<sup>25</sup> The strengths of our investigation include the moderate-sized community-based sample with long-term follow-up and assessment of both LVH prevalence and CVD incidence as outcomes. Our results must be interpreted with caution, however. First, our study could have benefited from a larger sample and greater number of CVD events to provide even more reliable estimates on the risks associated with a pulse pressure-arterial stiffness mismatch. Second, CFPWV is only a measure of large artery stiffness and does not adequately reflect stiffness or function of smaller conduit arteries. Third, our sample consisted mainly of older white individuals of European ancestry. Our results may not be generalizable to other races/ethnicities or age groups. Fourth, we opted to not adjust our models for antihypertensive treatment because it tracked closely with CPP/CFPWV

group membership, resulting in collinearity among predictor variables. Fifth, measurements for echocardiographic LVH were performed 1 examination cycle (≈3 years) preceding the CFPWV measurements.

## Perspectives

Mismatch between pulse pressure and arterial stiffness is common in the community, and caution should, therefore, be taken if contemplating on using pulse pressure as a surrogate marker of arterial stiffness. CPP may modify the effects of CFPWV on cardiovascular risk, with the greatest vascular risk being experienced when both CPP and CFPWV are elevated.

## Sources of Funding

This work was supported by the National Heart, Lung, and Blood Institute Framingham Heart Study (National Institutes of Health [NIH] contracts N01-HC-25195 and HHSN2682015000011) and NIH grants HL080124, HL071039, HL077447, HL107385, 1R01HL126136-01A1, 5R01HL107385-04, 1R01HL60040, and 1R01HL70100. R.S. Vasan is supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine.

## Disclosures

G.F. Mitchell is the owner of Cardiovascular Engineering, Inc—a company that designs and manufactures devices that measure vascular stiffness. The company uses these devices in clinical trials that evaluate the effects of diseases and interventions on vascular stiffness. The other authors report no conflicts.

## References

- Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham Heart Study. *Circulation*. 2010;121:505–511. doi: 10.1161/CIRCULATIONAHA.109.886655
- Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. *Circulation*. 1999;100:354–360.
- Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. *Hypertension*. 2004;43:1239–1245. doi: 10.1161/01.HYP.0000128420.01881.aa
- Mitchell GF, Wang N, Palmisano JN, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS. Hemodynamic correlates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study. *Circulation*. 2010;122:1379–1386. doi: 10.1161/CIRCULATIONAHA.109.914507
- Mackenzie IS, Wilkinson IB, Cockcroft JR. Assessment of arterial stiffness in clinical practice. *QJM*. 2002;95:67–74.

6. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. *Am J Epidemiol*. 1979;110:281–290.
7. Mitchell GF, Guo CY, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. *Circulation*. 2007;115:2628–2636. doi: 10.1161/CIRCULATIONAHA.106.667733
8. Brand M, Woodiwiss AJ, Michel F, Booyens HL, Veller MG, Norton GR. A mismatch between aortic pulse pressure and pulse wave velocity predicts advanced peripheral arterial disease. *Eur J Vasc Endovasc Surg*. 2013;46:338–346. doi: 10.1016/j.ejvs.2013.06.005
9. Kelly R, Fitchett D. Noninvasive determination of aortic input impedance and external left ventricular power output: a validation and repeatability study of a new technique. *J Am Coll Cardiol*. 1992;20:952–963.
10. Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, Chaudhary BS, Phillips MC. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. *J Am Coll Cardiol*. 1985;6:572–580.
11. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1.e14–39.e14. doi: 10.1016/j.echo.2014.10.003
12. Kannel WB, Wolf PA, Garrison RJ. *Section 34: Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death in Pooled Repeated Biennial Measurements. Framingham Heart Study, 30 Year Follow-Up*. Bethesda, MD: US Department of Health and Human Services; 1987.
13. Selvin S. *Statistical Analysis of Epidemiologic Data*. New York, NY: Oxford University Press; 1996.
14. Miljkovic D, Perret-Guillaume C, Alla F, Salvi P, Erpelding ML, Benetos A. Correlation between peripheral blood pressure and pulse-wave velocity values in the institutionalized elderly persons 80 years of age and older: the PARTAGE study. *Am J Hypertens*. 2013;26:163–173. doi: 10.1093/ajh/hps042
15. Nürmberger J, Dammer S, Opazo Saez A, Philipp T, Schäfers RF. Diastolic blood pressure is an important determinant of augmentation index and pulse wave velocity in young, healthy males. *J Hum Hypertens*. 2003;17:153–158. doi: 10.1038/sj.jhh.1001526
16. Kim EJ, Park CG, Park JS, Suh SY, Choi CU, Kim JW, Kim SH, Lim HE, Rha SW, Seo HS, Oh DJ. Relationship between blood pressure parameters and pulse wave velocity in normotensive and hypertensive subjects: invasive study. *J Hum Hypertens*. 2007;21:141–148. doi: 10.1038/sj.jhh.1002120
17. Kang J, Kim HL, Lim WH, Seo JB, Zo JH, Kim MA, Kim SH. Relationship between brachial-ankle pulse wave velocity and invasively measured aortic pulse pressure. *J Clin Hypertens (Greenwich)*. 2018;20:462–468. doi: 10.1111/jch.13200
18. Mitchell GF, Gudnason V, Launer LJ, Aspelund T, Harris TB. Hemodynamics of increased pulse pressure in older women in the community-based Age, Gene/Environment Susceptibility-Reykjavik Study. *Hypertension*. 2008;51:1123–1128. doi: 10.1161/HYPERTENSIONAHA.107.108175
19. Mitchell GF, Lacourcière Y, Ouellet JP, Izzo JL Jr, Neutel J, Kerwin LJ, Block AJ, Pfeffer MA. Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. *Circulation*. 2003;108:1592–1598. doi: 10.1161/01.CIR.0000093435.04334.1F
20. Farasat SM, Morrell CH, Scuteri A, Ting CT, Yin FC, Spurgeon HA, Chen CH, Lakatta EG, Najjar SS. Pulse pressure is inversely related to aortic root diameter implications for the pathogenesis of systolic hypertension. *Hypertension*. 2008;51:196–202. doi: 10.1161/HYPERTENSIONAHA.107.099515
21. Cecelja M, Jiang B, McNeill K, Kato B, Ritter J, Spector T, Chowienczyk P. Increased wave reflection rather than central arterial stiffness is the main determinant of raised pulse pressure in women and relates to mismatch in arterial dimensions: a twin study. *J Am Coll Cardiol*. 2009;54:695–703. doi: 10.1016/j.jacc.2009.04.068
22. Lemogoum D, Flores G, Van den Abeele W, Ciarka A, Leeman M, Degaute JP, van de Borne P, Van Bortel L. Validity of pulse pressure and augmentation index as surrogate measures of arterial stiffness during beta-adrenergic stimulation. *J Hypertens*. 2004;22:511–517.
23. Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. *Hypertension*. 2001;37:1429–1433.
24. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. *JAMA*. 2012;308:875–881. doi: 10.1001/2012.jama.10503
25. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation*. 2007;115:928–935. doi: 10.1161/CIRCULATIONAHA.106.672402

## Novelty and Significance

### What Is New?

- The prevalence and prognostic significance of a mismatch between central pulse pressure (CPP) and arterial stiffness (carotid-femoral pulse wave velocity [CFPWV]) in the community have not been well studied.
- Such information could be of interest to elucidate the validity of CPP as a surrogate measure of arterial stiffness and to help clinicians understand the relative and conjoint importance of CPP and arterial stiffness in the assessment and pathogenesis of cardiovascular disease risk.

### What Is Relevant?

- Thirty-nine percent of 2119 Framingham Offspring cohort participants had discordant CPP and CFPWW status

- Only participants with a high CPP with high CFPWW experienced significantly increased cardiovascular disease risk, and the interaction term between CPP and CFPWW status on cardiovascular disease risk was significant.

### Summary

Our results demonstrate that pulse pressure-arterial stiffness mismatch is common in the community. CFPWW may modify the association of CPP with cardiovascular disease risk, with the greatest risk being observed in those with elevated CPP and CFPWW.